Tesamorelin: Visceral Fat, Liver Fat and the Trials Behind It

At a Glance

Tesamorelin is the exception in this corner of the peptide world. It is a real medicine with phase 3 trials, a label, three marketed formulations and a defined indication. Where almost every GH-axis peptide offers mechanism and hope, tesamorelin offers imaging endpoints in hundreds of randomised patients.

The honest verdict has two halves. Inside its indication, tesamorelin does what it says: a reliable 15% relative reduction in visceral adipose tissue at 2 mg daily, with triglycerides and cholesterol ratios improving and subcutaneous fat left alone. Outside that population the evidence thins fast. The only randomised data in people without HIV are a two-week mechanistic study in 13 healthy men, a 12-week safety study in type 2 diabetes, and a single 20-week cognition trial. None of those measured fat loss in a metabolically healthy adult over months, which is what most off-label use is aiming at.

The second half of the verdict is about durability. Visceral fat returns after stopping. This is a treatment that works while it is being taken, not a one-off intervention.

How it works

GHRH is the hypothalamic peptide that tells pituitary somatotrophs to release growth hormone. Native GHRH(1-44) is destroyed within minutes by dipeptidyl peptidase-4. Tesamorelin attaches a trans-3-hexenoyl group to the N-terminus, which blocks that cleavage and gives the molecule enough half-life to work as a once-daily injection.

Because it acts at the top of the axis, the GH that rises is the patient’s own, released in pulses and still subject to somatostatin feedback. A two-week study in 13 men with a mean BMI of 27.3 made this concrete: 2 mg daily raised mean overnight GH, log GH peak area and basal GH secretion, and raised IGF-1 by 181 mcg/L, while fasting glucose and insulin-stimulated glucose uptake measured by euglycaemic clamp did not change significantly (Stanley 2011).

The visceral selectivity is the interesting part. GH is lipolytic, and visceral adipose tissue is more GH-responsive than subcutaneous fat. Across the trials, visceral fat fell while subcutaneous fat did not change significantly (Falutz 2010). That pattern is the opposite of what most weight-loss drugs do, and it is why tesamorelin was developed for a condition defined by central fat accumulation alongside peripheral fat loss.

What the evidence shows

Human trials, in order of weight

Phase 3, visceral fat. 412 patients with HIV and abdominal fat accumulation were randomised to 2 mg tesamorelin or placebo daily for 26 weeks. Visceral adipose tissue fell 15.2% with tesamorelin and rose 5.0% with placebo. Triglycerides fell 50 mg/dL versus a 9 mg/dL rise, the total cholesterol to HDL ratio fell 0.31 versus a 0.21 rise, and IGF-1 rose 81.0% versus a 5.0% fall, all at p<0.001 (Falutz 2007).

Pooled phase 3 with safety extension. Two multicentre studies pooled 806 patients randomised 2:1 to 2 mg tesamorelin or placebo for 26 weeks, then re-randomised for a further 26 weeks. The visceral fat treatment effect was 15.4%, subcutaneous fat did not change significantly, and triglycerides and cholesterol ratios improved (Falutz 2010). The re-randomisation matters practically: patients switched from tesamorelin to placebo lost the benefit.

Liver fat, randomised. 50 antiretroviral-treated men and women with abdominal fat accumulation received 2 mg daily or placebo for six months. Visceral fat fell with a treatment effect of 42 cm², and liver fat fell significantly on magnetic resonance spectroscopy (Stanley 2014). A larger 12-month trial in 61 people with HIV and a hepatic fat fraction of at least 5% found an absolute reduction of 4.1 percentage points versus placebo (95% CI −7.6 to −0.7), a 37% relative reduction, with 35% of the tesamorelin group versus 4% of placebo falling below 5% hepatic fat. Fasting glucose and HbA1c did not differ at 12 months, and injection-site complaints were more common on tesamorelin (Stanley 2019).

Glycaemic safety in diabetes. 53 patients with type 2 diabetes were randomised to placebo, 1 mg or 2 mg tesamorelin for 12 weeks. There were no significant between-group differences in insulin response after oral glucose, fasting glucose, HbA1c or overall diabetes control, and total and non-HDL cholesterol each fell by about 0.3 mmol/L in the 2 mg group (Clemmons 2017). Twelve weeks is short, but this is better glycaemic data than any other peptide in this family has.

Cognition. A 20-week randomised trial in 152 adults aged 55 to 87, with and without mild cognitive impairment, used 1 mg daily and found improvement in a cognitive composite driven by executive function (Baker 2012), with a spectroscopy substudy showing raised brain GABA (Friedman 2013). A 2025 six-month open-label phase 2 trial in 73 people with HIV, abdominal obesity and neurocognitive impairment compared 2 mg daily with standard care; waist circumference fell without a clear cognitive difference (Ellis 2025). The full argument about that single positive cognition trial is in Tesamorelin and the Aging Brain.

What the evidence does not show

No randomised trial of tesamorelin for fat loss, body composition or performance in adults without HIV. No trial of cycling it. No long-term cancer or mortality data. The current review of GH-axis peptides notes that off-label positioning of tesamorelin for recovery, anti-inflammatory effects and physique goals extends well beyond the trial endpoints (Dominikowski 2026).

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Why the three label doses differ. The formulations deliver different exposure. The original Egrifta used 1 mg vials at 2 mg daily; Egrifta SV uses a 2 mg vial at 1.4 mg daily to give exposure similar to the original 2 mg dose; Egrifta WR uses an 11.6 mg vial reconstituted weekly, dosed at 1.28 mg daily. The numbers are not interchangeable, and a vial sold as “tesamorelin” without a label carries none of that calibration.

Titration as it is actually done. Off-label practice patterns start at 1 mg daily for two to four weeks, watching fluid retention, joint discomfort and glucose, then move to 2 mg. The trials did not titrate.

Duration and what happens afterwards. Trials ran 26 weeks to 12 months. Visceral fat returns after discontinuation, which the re-randomisation arm of the pooled analysis showed directly (Falutz 2010). Practice protocols often run shorter 12 to 16 week blocks, which is usually a cost decision rather than a clinical one.

Technique, reconstitution and storage are in the peptide injection guide.

What people report: what works and what doesn’t

Sources: the aggregated community data sets (Peptide Protocol Wiki, 100 reports; Peptide DB), the off-label protocol patterns in the peer-reviewed review (Dominikowski 2026), and the trial data above. Patterns, not proof.

Reported to work

• Loss of abdominal girth over 8 to 16 weeks at 2 mg daily, often described as the waist changing more than the scale. This is the one off-label claim that lines up with the trial mechanism, since visceral fat weighs little but occupies the abdomen.
• Better sleep in the first weeks, consistent with a nocturnal GH pulse.
• A clear IGF-1 rise in people who test, which the trials confirm at both 1 mg and 2 mg.
• Improved triglycerides and cholesterol ratios in people who check lipids, matching the phase 3 secondary endpoints.

Mixed or unclear

• Fat loss in people who are already lean. Reports are much weaker here, and the trials were done in a population defined by visceral fat excess. There is no reason to expect the same effect size in someone without that phenotype.
• Cognitive and mood effects. Occasionally reported, supported by one 20-week trial in older adults, never replicated.
• Whether 1 mg is enough. Practice is split, and both doses were studied, in different trials with different endpoints.
• Research-grade product versus pharmacy product. People who have used both often describe different responses. Unverifiable, but plausible given what analytical surveys find in grey-market peptides.

Reported not to work, or disappointing

• Fat staying off after stopping. The most common complaint, and the trials predict it.
• Muscle gain. Tesamorelin does not produce it in any trial, and reports of it are rare and confounded.
• Side effects people stop for: injection-site redness and nodules, which were the most frequent adverse event in the liver-fat trial, arthralgia, peripheral oedema, paraesthesia, and in some cases rising fasting glucose despite the reassuring 12-week diabetes data.
• Cost. Mentioned more often in off-label discussion than any side effect.

What a properly designed trial would need to show: a randomised, placebo-controlled trial of 6 to 12 months in adults without HIV who have visceral adiposity, with imaging-based visceral and hepatic fat, lean mass, insulin sensitivity by clamp or oral glucose tolerance test, and a defined follow-up period after stopping.

Safety and side effects

From the trials and label. Injection-site reactions were the most common adverse events, including erythema, pruritus and nodules. Arthralgia, myalgia, peripheral oedema and paraesthesia appear across the GH-axis literature. The label carries warnings for glucose intolerance and diabetes, fluid retention and neoplasia, and lists active malignancy and pregnancy as contraindications.

Glucose. Three independent data points are reassuring over weeks to months: no change in clamp-measured insulin sensitivity after two weeks in healthy men (Stanley 2011), no deterioration in glycaemic control over 12 weeks in type 2 diabetes (Clemmons 2017), and no difference in fasting glucose or HbA1c at 12 months in the liver-fat trial (Stanley 2019). That is better evidence than any other peptide here can offer, and still not a licence to skip monitoring.

IGF-1 and neoplasia. IGF-1 rose 81% in the pivotal trial. Higher circulating IGF-1 associates with prostate and premenopausal breast cancer risk in epidemiological data (Renehan 2004), the label warns about neoplasia, and the question of years of treatment is unresolved. Baseline and periodic IGF-1 measurement is the minimum standard in my reading.

Contraindications and cautions. Active malignancy. Pregnancy. Disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, pituitary tumour or surgery, or head irradiation, per the label. Caution alongside insulin or insulin secretagogues, because GH opposes insulin action.

Grey-market product. Tesamorelin is a 44-amino-acid peptide and considerably harder to synthesise correctly than a hexapeptide. Analytical surveys of seized peptide products repeatedly find wrong identity, wrong content and degradation products (Weber 2017), and the trial results belong to the GMP product, not to a vial carrying the same name. See peptide sourcing.

Legal and regulatory status

United States. Approved. FDA licensed tesamorelin in November 2010 as Egrifta to reduce excess abdominal fat in HIV-infected patients with lipodystrophy, and the newer Egrifta SV and Egrifta WR formulations carry the same indication at different daily doses. Prescribing it for anything else is off-label use of an approved drug, which is lawful for a physician and not the same thing as evidence. One distinction from the rest of this library: because tesamorelin is an approved drug product, it does not need to appear on FDA’s bulk-substance compounding lists, and a research-grade vial is a different thing entirely from the licensed product.

European Union and Germany. Not authorised. The EU marketing application was withdrawn in June 2012 after the CHMP’s provisional view that the benefit-risk balance could not be established. Tesamorelin is named in the annex to Germany’s Anti-Doping Act (AntiDopG) under growth hormone releasing factors, where § 2(3) makes it an offence to acquire, possess or import more than a “non-small quantity” for the purpose of doping in sport; the quantity regulation (DmMV, in force 16 March 2023) sets that threshold at 180 mg for the GHRH analogue group, two orders of magnitude above the 1.5 mg threshold that applies to the GHRPs.

Sport. Prohibited at all times under section S2 of the WADA list, which covers GHRH and its analogues explicitly. No therapeutic use exemption is granted for performance purposes. See peptides and anti-doping rules.

How tesamorelin fits

Tesamorelin is the only peptide in this part of the library I would call a drug rather than a research compound. Within its indication the evidence is genuinely strong. Outside it, the argument is extrapolation from a different population, which can be reasonable but should be named as what it is.

For the head-to-head with the secretagogue combination that dominates practice, see CJC-1295/Ipamorelin vs Tesamorelin. For the wider GHRH family, Sermorelin vs CJC-1295 covers how half-life and pulsatility differ.

Related Articles

• CJC-1295/Ipamorelin vs Tesamorelin: Growth Hormone Secretagogues Compared — the direct comparison.
• Tesamorelin and the Aging Brain: One Trial, Many Questions — the cognition evidence in detail.
• Sermorelin vs CJC-1295: Which Growth Hormone Peptide Is Right for You? — the other GHRH analogues.
• AOD 9604: The hGH Fragment for Fat Loss and Tissue Repair — the fragment approach to fat loss, without IGF-1 elevation.
• Peptide Therapy for Athletes: What’s Banned Under WADA Rules in 2026 — why an approved drug is still prohibited in sport.